Skip to main content
SpringerLink
Log in
Book cover

Crohn's Disease and Ulcerative Colitis pp 441–448Cite as

Biologic Therapy of Ulcerative Colitis: Golimumab

  • Chapter
  • First Online:

  • 3451 Accesses

Abstract

Golimumab is an anti-tumor necrosis factor (TNF) agent, which both induces and maintains response and remission in moderate to severe ulcerative colitis (UC). Its efficacy was demonstrated during an integrated phase 2 and 3, randomized, placebo controlled, trial program (PURSUIT, Program of Ulcerative colitis Research Studies Utilizing an Investigational Treatment). It is administered subcutaneously, and after induction doses given 2 weeks apart, maintenance therapy is given on a 4 weekly dosing schedule. Clinical trial data, as well as previous experience in rheumatoid disease, has demonstrated its safety, and its use has been approved by regulating bodies in Europe and the USA. However, questions still remain regarding the optimal use of golimumab and its positioning in relation to other biological therapies for UC.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Abbreviations

UC:

Ulcerative colitis

QoL:

Quality of fife

TNF:

Tumor necrosis factor

MH:

Mucosal healing

CRP:

C-reactive protein

PURSUIT:

Program of Ulcerative colitis Research Studies Utilizing an Investigational Treatment

ACT:

Active ulcerative colitis trials

ULTRA:

Ulcerative colitis long-term remission and maintenance with adalimumab

References

  1. Hutas G. Golimumab, a fully human monoclonal antibody against TNFalpha. Curr Opin Mol Ther. 2008;10(4):393–406.

    CAS  PubMed  Google Scholar 

  2. Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol. 2005;23(9):1117–25.

    Article  CAS  PubMed  Google Scholar 

  3. Lowenberg M, de Boer N, Hoentjen F. Golimumab for the treatment of ulcerative colitis. Clin Exp Gastroenterol. 2014;7:53–9. Pubmed Central PMCID: 3958527.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Shealy DJ, Cai A, Staquet K, Baker A, Lacy ER, Johns L, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. mAbs. 2010;2(4):428–39. Pubmed Central PMCID: 3180089.

    Article  PubMed  Google Scholar 

  5. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85–95.

    Article  CAS  PubMed  Google Scholar 

  6. Feagan BG, Sandborn WJ, D’Haens G, Pola S, McDonald JW, Rutgeerts P, et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology. 2013;145(1):149–57.e2.

    Google Scholar 

  7. Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137(4):1250–60. quiz 520.

    Google Scholar 

  8. Hanauer SB. Still in pursuit. Gastroenterology. 2014;146(1):13–5.

    Article  PubMed  Google Scholar 

  9. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76.

    Article  CAS  PubMed  Google Scholar 

  10. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257–65.e1–3.

    Google Scholar 

  11. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):96–109.e1.

    Google Scholar 

  12. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107(9):1409–22. Pubmed Central PMCID: 3438468.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. D'Haens G, Reinisch W, Satsangi J, Loftus E, Panaccione R, Tokimoto D, et al. PYRAMID registry: an observational study of adalimumab in Crohn’s disease: results at year 3. Inflamm Bowel Dis. 2011;17:S21.

    Article  Google Scholar 

  14. Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, et al. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomized, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis. 2015;74(3):538–46. Pubmed Central PMCID: 4345908.

    Article  CAS  PubMed  Google Scholar 

  15. Mease PJ. Adalimumab in the treatment of arthritis. Ther Clin Risk Manag. 2007;3(1):133–48. Pubmed Central PMCID: 1936294.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kneepkens EL, Plasencia C, Krieckaert CL, Pascual-Salcedo D, van der Kleij D, Nurmohamed MT, et al. Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice. Ann Rheum Dis. 2014;73(12):2217–9.

    Article  CAS  PubMed  Google Scholar 

  17. Danese S, Fiorino G, Peyrin-Biroulet L, Lucenteforte E, Virgili G, Moja L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med. 2014;160(10):704–11.

    Article  PubMed  Google Scholar 

Download references

Disclosures

Mark A. Samaan—Hospira: Advisory board and training, Takeda: Lecturing.

Peter M. Irving—Honoraria for acting in an advisory capacity or speaking on behalf of MSD, Abbvie, Takeda, Shire, Ferring, Tillott’s Pharma, Warner Chilcott, Genentech, Pharmacosmos. Research support: MSD.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Guy’s and St Thomas’ Hospital, First Floor College House, North Wing, St Thomas’ Hospital, Westminster Bridge Road, London, SE1 7EH, UK

    Mark A. Samaan & Peter M. Irving

Authors
  1. Mark A. Samaan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter M. Irving
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter M. Irving .

Editor information

Editors and Affiliations

  1. Inflammatory Bowel Disease Center, Department of Gastroenterology and Hepatology, Charité Medical School—Humboldt-University of Berlin, Berlin, Germany

    Daniel C. Baumgart

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Samaan, M.A., Irving, P.M. (2017). Biologic Therapy of Ulcerative Colitis: Golimumab. In: Baumgart, D. (eds) Crohn's Disease and Ulcerative Colitis. Springer, Cham. https://doi.org/10.1007/978-3-319-33703-6_44

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-33703-6_44

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-33701-2

  • Online ISBN: 978-3-319-33703-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation